Danaher Reports Strong Q3 2026 Results Driven by Bioprocessing and Operational Execution
Danaher Corporation (DHR) reported third-quarter 2026 results that exceeded internal projections, with total revenue reaching $6.6 billion, an 8.5% increase year-over-year. Despite a significant headwind from declining respiratory testing revenue, the company achieved an adjusted diluted EPS of $2.11, representing an 11.5% increase. Core revenue growth excluding respiratory segments accelerated to 5.5%, supported by strong performance in biotechnology and life sciences. The company demonstrated high-quality earnings with a free cash flow of $1.6 billion for the quarter and a year-to-date conversion rate of 128%. Strategic moves included the acquisition of StatLab to bolster oncology pathology workflows and an announced partnership with NVIDIA to integrate AI into robotic lab workflows. Management raised its full-year 2026 adjusted EPS guidance, signaling confidence in continued operational momentum despite fluctuations in respiratory demand.
Topics: Biotechnology Diagnostics EPS Financial Performance Free Cash Flow Revenue Growth
Read the full article at Motley Fool
Part of the story Moody's Reports Strong Q3 2026 Results Driven by AI Infrastructure and Debt Refinancing (10 articles)